Thomas Spires
Senior Director, Translational Medicine Bristol Myers Squibb
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficacy
1:00 pm
- Â Uncovering the current status and unmet medical needs for patients with RAS-driven cancers, what cancers need more improved response rates?
- What genomic features predict poor response and outcomes for RAS-targeting therapies?
- How do you successfully overcome or delay resistance to RAS-targeting therapies?
Tuesday 16th September 2025
Enhancing Anti-Tumor Immunity by Combining KRAS inhibition with Immune Checkpoint Blockade to Improve Treatment Responses
1:15 pm
- Overcoming the immunosuppressive tumor microenvironment (TME) of KRAS-mutant tumors
- Improving understanding of the influence KRAS inhibition on tumor immune responses to increase effectiveness of immune therapies
- Exploring combination strategies to overcome challenges posed by the TME and tumor stroma
